Loading
Led the Canadian trials that established three-week breast radiotherapy and defined when nodal radiotherapy helps.
Timothy Whelan led the Ontario hypofractionation trial showing 16 fractions over three weeks matches 25 fractions for breast conservation, which with the UK START trials moved the world to shorter schedules, and MA.20, which showed regional nodal irradiation reduces recurrence in node-positive disease. He led the LUMINA study showing radiotherapy can be omitted in low-risk luminal A breast cancer and chairs the CCTG breast site.
Shares IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer and the tags radiotherapy, breast.
Shares IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer and the tags radiotherapy, breast.
Shares IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer and the tags radiotherapy, breast.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares HR-positive / HER2-negative breast cancer and the tag breast.
Shares HR-positive / HER2-negative breast cancer and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.